Cigarette Smoke Enhances Beta-Defensin 2 Expression in Rat Airways Via Nuclear Factor-Kappa B Activation
L. Chen,B-B. Sun,T. Wang,X. Wang,J-Q. Li,H-X. Wang,S-F. Zhang,D-S. Liu,L. Liu,D. Xu,X-M. Ou,Y-J. Chen,T. Yang,H. Zhou,F-Q. Wen
DOI: https://doi.org/10.1183/09031936.00029409
2010-01-01
Abstract:beta-defensin 2 (BD-2), an antimicrobial peptide, participates in airway defence. Cigarette smoke (CS) is a major risk factor for the development of chronic obstructive pulmonary disease. This study mainly aims to investigate the effect of CS on rat BD-2 (rBD-2) expression in rat airways.Rats were exposed to CS and treated with caffeic acid phenethyl ester (CAPE), a nuclear factor (NF)-kappa B inhibitor, or astragaloside IV (AS-IV), an active ingredient of Astragalus mongholicus. Besides the analysis of bronchoalveolar lavage fluid (BALF) and histological changes after CS exposure, rBD-2 expression was investigated with immunohistochemistry, reverse transcription PCR and ELISA. Total glutathione and nitric oxide (NO) levels in rat lungs were also detected.CS exposure markedly increased rBD-2 immunoreactivity, as well as rBD-2 mRNA and protein levels in rat airways, which were inhibited by CAPE treatment. Moreover, associated airway inflammation induced by CS was demonstrated by histological changes, increased cell counts and pro-inflammatory cytokines in BALF, and NF-kappa B activation and high levels of total glutathione and NO, which were all reversed by AS-IV in a dose-dependent fashion.In conclusion, CS exposure induces rBD-2 expression in rat airways via a NF-kappa B-dependent pathway, and AS-IV attenuates CS-induced airway inflammation due to its anti-inflammatory and antioxidant properties, at least partly through NF-kappa B inactivation.